Refine by
Antigen Target Suppliers & Manufacturers
49 companies found
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell ...
based inShanghai, CHINA
Focusing on the core raw materials of the life science industry, Yeasen Biotechnology (Shanghai) Co., Ltd. is a biotechnology company engaged in the research and development, production and sales of three major categories of biological reagents: ...
based inSan Francisco, CALIFORNIA (USA)
Icosagen is a research-driven contract research provider for biopharmaceutical and biotechnology industries that deftly adapts to market forces and current trends, and is always guided by the needs of its customers. The Group comprises four ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inVancouver, BRITISH COLUMBIA (CANADA)
STEMCELL Technologies provides high-quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources to scientists around the world working on stem cell, immunology, cancer, regenerative medicine, ...
based inSouth San Francisco, CALIFORNIA (USA)
At Twist Bioscience, we work in the service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, our customers are developing ways ...
The human anti-ACE2 receptor antibodies exhibit high affinity to the ACE2 receptor indicating that they have the potential to be developed as blocking or competitive antibodies for therapeutic ...
based inGembloux, BELGIUM
Based in Belgium and established in 1996, Coris BioConcept is a middle-sized company (SME) specialized in developing, manufacturing and marketing rapid diagnostic kits for the detection of human respiratory, gastro-enteric and blood-borne pathogens ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Senti Bio has established, and continues to scale, a powerful Design-Build-Test-Learn development engine to generate our therapeutic gene circuits. Unique to Senti Bio’s approach is the speed, quantity and quality of the multiple types of gene ...
based inSan Diego, CALIFORNIA (USA)
Founded originally in Vancouver, British Columbia in 2006 by three enthusiastic entrepreneurs passionate about providing the best biological reagents worldwide, MyBiosource, Inc. was incorporated as a company with big visions. Since 2007, we have ...
Product Gene Name: ADP elisa kit. Research Use Only: For Research Use Only. Not for use in diagnostic ...
based inMadison, WISCONSIN (USA)
Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ...
NeoClone is a world-class custom antibody development company, having discovered hundreds of antibodies for our clients. But there are very difficult targets out there that hybridoma technology alone can't solve. So we added antibody phage display ...
based inCoelbe, GERMANY
Convergent Technologies is an emerging leader in the field of Integrated Healthcare Solutions. We strive to provide innovative and cost-effective healthcare solutions enabling people live healthier lives. Our state-of-the-art diagnostic test and ...
The Convergys® COVID-19 Rapid Antigen Test is designed for the direct testing for acute COVID-19 infections. The rapid chromatographic immunoassay detects the Nucleocapsid protein of SARS-CoV-2, the pathogen causing the COVID-19 disease. Results ...
based inDallas, TEXAS (USA)
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology ...
based inBerlin, GERMANY
The BioTeZ Berlin-Buch GmbH is a Biotechnology company founded in 1992. BioTeZ is partner of research institutions, the pharmaceutical industry and laboratory diagnostics. Our sister company Steffens-Biotec, Ebringen (ISO 13485) is specialised in ...
based inMons, BELGIUM
D-tek s.a. is a private Belgian biotechnology company created in 1995 in Mons (40 km from Brussels and less than 1h20 from Paris). The company is located in 1.200 square meters facilities in the Scientific Park Initialis of Mons. The company is ...
The M2 antibodies belong to the group of Anti-Mitochondrial Antibodies (AMA) and are strongly associated with PBC. At least 9 distinct AMA have been identified, which have been classified M1-M9 according to their antigen specificity and disease ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many ...
based inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
based inVannas, SWEDEN
Agrisera is a Swedish company, established in 1985, specialized in antibody production and purification. Since 2020, Agrisera is a part of Olink Group. Agrisera provides off-the-shelf antibodies for plant and algal research, with prompt delivery ...
The Rubisco quantitation kit is suitable for quantitation of Rubisco in plant and algal samplesusing quantitative immunoblotting. It contains anti-RbcL antibody, Rubisco protein standard and theProtein Extraction Buffer for quantitative protein ...
based inKrakow, POLAND
We are one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. We have ...
Cell and Molecular Biology Department at Selvita performs In vitro comparative studies of biosimilar insulins and insulin analogs as well as battery of various therapeutic antibodies (e.g. TNFα, VEGF and HER2 inhibitors etc.). These studies ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
ADCs are not one-size-fits-all. The Dolasynthen platform enables an iterative approach to develop the right ADC for a given indication through customization and optimization. Dolasynthen utilizes a synthetic scaffold for precise control of DAR (from ...